Related Experiment Videos
CD44 expression predicts disease outcome in localized large B cell lymphoma
P Drillenburg1, V J Wielenga, M H Kramer
1Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands.
Leukemia
|September 14, 1999
Summary
CD44 expression predicts prognosis in diffuse large B cell lymphoma (DLCL). CD44 standard form (CD44s) refines the International Prognostic Index (IPI) for nodal DLCL patients, improving outcome prediction.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Diffuse large B cell lymphomas (DLCL) are heterogeneous with unknown biological drivers of varied prognosis.
- The lymphocyte homing receptor CD44 is a potential determinant of lymphoma dissemination.
Purpose of the Study:
- To investigate CD44 expression (CD44s and CD44v6) as a prognostic marker in DLCL.
- To assess if CD44 can refine the International Prognostic Index (IPI).
Main Methods:
- Immunohistochemistry was used to evaluate CD44s and CD44v6 expression.
- A cohort of 276 DLCL patients from a population-based registry was analyzed.
Main Results:
- CD44s and CD44v6 expression correlated with tumor dissemination in primary nodal DLCL.
- CD44s independently predicted tumor-related death in localized nodal DLCL, outperforming IPI parameters.
- Incorporating CD44s into the IPI 'stage' parameter enhanced its prognostic value for nodal DLCL.
Conclusions:
- CD44 is a significant biological prognosticator in DLCL.
- CD44s can be used to 'fine-tune' the IPI for improved prognostication in nodal DLCL.